Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis

11 Jul 2010

Abstract excerpt

RATIONALE: Nonsense (premature stop codon) mutations in mRNA for the cystic fibrosis transmembrane conductance regulator (CFTR) cause cystic fibrosis (CF) in approximately 10% of patients. Ataluren (PTC124) is an oral drug that permits ribosomes to readthrough premature stop codons in mRNA to produce functional protein. OBJECTIVES: To evaluate ataluren activity, safety, and pharmacokinetics in children with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biochemical Analysis and Sensing Techniques
Share to Congenital Ear and Nasal Anomalies
Share to Cystic Fibrosis Research Advances

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20622033
DOI: 10.1164/rccm.201001-0137oc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic FibrosisPMID 20622033Read ↗

Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosisSemantic proximity Read ↗

Ataluren in cystic fibrosis: development, clinical studies and where are we now?Semantic proximity Read ↗

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosisSemantic proximity Read ↗

Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF)Semantic proximity Read ↗

Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis.Semantic proximity Read ↗

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.Semantic proximity Read ↗

Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids.Semantic proximity Read ↗

Ataluren: first global approval.Semantic proximity Read ↗

No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations.Semantic proximity Read ↗

Phase 2a Study of Ataluren-Mediated Dystrophin Production in Patients with Nonsense Mutation Duchenne Muscular DystrophySemantic proximity Read ↗

Synthetic Aminoglycosides Efficiently Suppress Cystic Fibrosis Transmembrane Conductance Regulator Nonsense Mutations and Are Enhanced by IvacaftorSemantic proximity Read ↗

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.